Abstract
Osteosarcoma (OS) is one of the most serious malignancies along with a high incidence in children and teenagers. Although the neoadjuvant chemotherapy of OS has made great progress and prolongs the five-year survival rates of patients to some extent, drugs are restrained from clinical application due to the unsatisfactory efficacy and severe side effects, especially for the systemic therapy through intravenous injection. The polymeric nanoparticles as anti-cancer drug nanocarriers make OS treatment more promising and effective. Specifically, various polymeric nanoparticles have been developed to overcome the difficulties in targeting delivery of drugs to OS tissue and/or cells through passive and/or active strategies. This review presents an overview on the development of polymeric nanoparticles for anti-cancer drug delivery in OS treatment, and briefly describes the challenge and opportunity for future development.
Keywords: Active targeting, controlled drug delivery, osteosarcoma therapy, passive targeting, polymeric nanocarriers.
Current Pharmaceutical Design
Title:Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment
Volume: 21 Issue: 36
Author(s): Xueyuan Gu, Jianxun Ding, Zhiyu Zhang, Qin Li, Xiuli Zhuang and Xuesi Chen
Affiliation:
Keywords: Active targeting, controlled drug delivery, osteosarcoma therapy, passive targeting, polymeric nanocarriers.
Abstract: Osteosarcoma (OS) is one of the most serious malignancies along with a high incidence in children and teenagers. Although the neoadjuvant chemotherapy of OS has made great progress and prolongs the five-year survival rates of patients to some extent, drugs are restrained from clinical application due to the unsatisfactory efficacy and severe side effects, especially for the systemic therapy through intravenous injection. The polymeric nanoparticles as anti-cancer drug nanocarriers make OS treatment more promising and effective. Specifically, various polymeric nanoparticles have been developed to overcome the difficulties in targeting delivery of drugs to OS tissue and/or cells through passive and/or active strategies. This review presents an overview on the development of polymeric nanoparticles for anti-cancer drug delivery in OS treatment, and briefly describes the challenge and opportunity for future development.
Export Options
About this article
Cite this article as:
Gu Xueyuan, Ding Jianxun, Zhang Zhiyu, Li Qin, Zhuang Xiuli and Chen Xuesi, Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment, Current Pharmaceutical Design 2015; 21 (36) . https://dx.doi.org/10.2174/1381612821666150923095618
DOI https://dx.doi.org/10.2174/1381612821666150923095618 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry The PAX8 / PPARγ Fusion Oncogene as a Potential Therapeutic Target in Follicular Thyroid Carcinoma
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy
Current Pharmaceutical Design Current Challenges in Targeting Tumor Desmoplasia to Improve the Efficacy of Immunotherapy
Current Cancer Drug Targets Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Drug Coated Clay Nanoparticles for Delivery of Chemotherapeutics
Current Nanoscience Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine
Current Drug Targets Update on Antifolate Drugs Targets
Current Drug Targets